Skip to content
Screener

Supernus Pharmaceuticals SUPN Business Segments — Marketing expenses

Similar metrics at other companies

OLP
OLPXReportable Segment — Marketing expenses
$26.04M+43.8%
ARH
ARHSReportable Segment — Marketing expenses
$10.94M+10.8%
Torrid Holdings logo
CURVReportable Segment — Marketing expenses
$14.54M-5.3%
Beyond Meat logo
BYNDReporting Segment — Marketing expenses
$9.43M+16.9%
V.F. Corporation logo
VFCActive — Marketing expenses
$56.09M+5.6%
V.F. Corporation logo
VFCOutdoor — Marketing expenses
$83.98M+17.3%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+21.8%
Enterprise value$2.63B+21.5%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:MarketingExpense.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Less: Significant segment expenses:
Cost of revenues23,39115,763
Selling expenses66,27842,614
Marketing expenses20,69720,664
General and administrative expenses38,19826,666
Research and development expenses
External development program expenses:
ONAPGO261472

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's business segments — marketing expenses?
Supernus Pharmaceuticals (SUPN) reported business segments — marketing expenses of $20.7M in Q1 2026.
How has Supernus Pharmaceuticals's business segments — marketing expenses changed year-over-year?
Supernus Pharmaceuticals's business segments — marketing expenses increased by 0.2% year-over-year, from $20.66M to $20.7M.
What is the long-term trend for Supernus Pharmaceuticals's business segments — marketing expenses?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — marketing expenses has grown at a -13.1% compound annual growth rate (CAGR), from $120.5M to $78.96M.
What does business segments — marketing expenses mean?
Reflects the investment in advertising, promotional campaigns, and brand awareness initiatives for the segment's product portfolio. This spending is essential for sustaining long-term market position and competitive advantage in the neuroscience space.

Ask your AI about Supernus Pharmaceuticals's business segments — marketing expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude